STADAPHARM GmbH
Location
Hessen
Founded
1993-02-24
Website
Risk Signals
622 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, In Vitro and In Vivo Diagnostic Substances, Patent Owners and Lessors, Business Services, Not Elsewhere Classified, Engineering Services, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about STADAPHARM GmbH
Live alerts from global media, monitored by Business Radar
2025-05-20 (monitor-versorgungsforschung.de)
Basem Yazgi leads generic business at Stada - Monitor supply research
Basem Yazgi (38) took over the operational responsibility for the generic business at Stada in early May. As Head of Generics Germany, Vice President at Stada and General Manager Aliud Pharma, he guides the fortunes of the generic segment from Laichingen. He succeeds Melania Pahor, who leaves Aliud and the Stada Group. In his new role, Yazgi reports directly to Stada Germany and Western Europe boss Dr. Stephan Eder and is a member of Stada's German Senior Executive Committee.
Read more
2020-02-11 (fr.de)
Pharmaceutical company Stada in Bad Vilbel creates jobs
The company grew at double-digit rates in 2019. New products create more demand in sales.
Read more
2010-07-06 (apotheke-adhoc.de)
Stada releases 800 employees |
The generic concentant Stada wants to improve its results with restructuring and a massive job cuts: the group wants to dismantle a total of 800 full -time positions, i.e. 10 percent of those at Stada. The focus will be outside of Germany, the company said.
Read more